Sanofi Halts Amlitelimab Development for Atopic Dermatitis, Dealing Blow to Dupixent Succession Pipeline

The Quick Take

• Sanofi has discontinued clinical development of Amlitelimab for moderate-to-severe atopic dermatitis, the hoped-for next-generation successor to blockbuster Dupixent
• The pipeline failure removes a key growth asset from Sanofi's dermatology franchise and raises questions about the long-term Dupixent succession plan
• Amlitelimab's discontinuation is a significant setback for Sanofi's immunology pipeline, which investors had expected to sustain growth beyond Dupixent's patent cliff

French pharmaceutical giant Sanofi has halted clinical development of Amlitelimab for the treatment of moderate to severe atopic dermatitis, known in German medical terminology as Neurodermitis. The drug had been positioned as the most promising candidate to extend Sanofi's dermatology franchise beyond Dupixent, its multi-billion-dollar interleukin-4/13 antibody that dominates the severe atopic dermatitis treatment landscape. The failure is reported by Aktiencheck News citing a dpa-AFX dispatch from Paris, confirming the clinical development discontinuation. Sanofi's stock will face pressure as Amlitelimab had been embedded in consensus forecasts as a key 2028-2032 revenue contributor post Dupixent's anticipated patent exposure.

The market implications are material for Sanofi's long-term growth narrative. Dupixent generated approximately €13 billion in annual revenues in 2025 and remains Sanofi's single largest product, but its intellectual property protection window is finite. Amlitelimab was the most advanced internal candidate positioned to absorb declining Dupixent revenues through new mechanisms and potentially expanded indications. Without it, Sanofi's dermatology succession pipeline is thinner. Competitors in the immunology space — AbbVie (Rinvoq), Eli Lilly (Lebrikizumab), Pfizer (Cibinqo) — will benefit from one fewer competitive threat in the severe atopic dermatitis development landscape, and their respective clinical pipelines gain relative value.

Investors should watch Sanofi management's response at the next investor day for clarity on the revised Dupixent succession strategy. The key variables are whether Sanofi accelerates in-licensing of external pipeline assets to fill the Amlitelimab gap, and whether Dupixent's new indication expansions (COPD, prurigo nodularis) can extend its revenue trajectory long enough to bridge to the next generation. The failure also raises questions about the translatability of mechanism-based atopic dermatitis research, which may affect valuation multiples applied to the broader dermatology biotech sector.

Synthesized from 2 sources.